Whalesbook
Balaji Amines recently reported a strong quarter-over-quarter improvement in its financial results, boosted by better product pricing and a 6% increase in sales volume. The company's standalone operations were the main driver of this performance. Meanwhile, its subsidiary, Balaji Speciality, operated at a lower capacity due to necessary repair work, which helped reduce the subsidiary's operating costs.
Standalone Business to Drive FY27 Growth
Management projects a 20-30% volume growth for its standalone business in fiscal year 2027. This increase is expected to come from the launch of three new plants and a rebound in a key emerging market segment. The new Dimethyl Ether (DME) plant, with a capacity of 100,000 tonnes, is currently being commissioned. Balaji Amines forecasts 30-40% utilization for this plant in its first year. The company sees DME as a potential alternative to LPG for industrial uses and aerosol products, subject to receiving necessary transportation approvals.
Capacity Expansion and Upgrades
To expand its production capabilities, Balaji Amines is upgrading its acetonitrile plant with new technology. This upgrade is scheduled for commissioning by the second quarter of fiscal year 2027. Additionally, a 5,000-tonne N-Methyl Morpholine (NMM) plant is on track to be commissioned in fiscal year 2027. NMM is targeted for use in pharmaceuticals, adhesives, PU foams, and textiles. The company also expects its Electronic Grade Battery Chemicals (DMC) plant to increase its utilization. This plant has seen limited use due to delays from domestic buyers, but commercial orders are anticipated to stabilize and begin fully in fiscal year 2027.
Capex Focus on Specialty Business
Balaji Amines plans to invest approximately Rs 280 crore in capital expenditure for fiscal year 2027. Of this amount, Rs 250 crore will be allocated to the Specialty business. This includes a brownfield project for Ethylene Diamine-based derivative products, which is expected to be commissioned in the first half of fiscal year 2027. The first phase of a greenfield Sodium Cyanide derivatives project is now projected for completion by the fourth quarter of fiscal year 2027.
Outlook and Risks
The company anticipates a 10-15% volume growth for fiscal year 2027 and expects its EBITDA margin to be between 22-23%. While prices for key raw materials like ammonia and methanol are high, the company believes its sourcing strategy is manageable. A significant risk for the company is potential delays in project execution and approvals, a factor considering its past performance. However, Balaji Amines' strategy of focusing on import substitution, especially by offering an alternative to LPG, and its market positioning are viewed positively. Despite an increase in trade receivables, the company's strong operating cash flows and solid balance sheet provide support for its ongoing capital expenditure program. Currently trading at an Enterprise Value to EBITDA ratio of 10.5 times its estimated fiscal year 2028 earnings, the stock appears reasonably valued given its earnings prospects and its efforts in import substitution.